EVM
RGNX icon

Eaton Vance Management’s Regenxbio RGNX Stock Holding History

Eaton Vance Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-597
Closed -$20K – 2506
2021
Q4 		$20K Sell
597
-85
-12% -$2.89K ﹤0.01% 2401
2021
Q3 		$3K Buy
682
+294
+76% +$10.6K ﹤0.01% 1891
2021
Q2 		$15K Buy
388
+239
+160% +$8.55K ﹤0.01% 2483
2021
Q1 		$5K Buy
+149
New +$6.36K ﹤0.01% 2613

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eaton Vance Management's RGNX Position: Q1 2022 in Review

Eaton Vance Management sold out of Regenxbio (RGNX) in Q1 2022, closing a stake of 597 shares — an estimated $20K sold.

Eaton Vance Management first reported a position in RGNX in Q1 2021 and held it in 4 quarters. The position peaked at $20K in Q4 2021. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2022.

  • Eaton Vance Management reported no remaining Regenxbio position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 597 Regenxbio shares in Q1 2022, an estimated $20K.
  • Eaton Vance Management first reported a position in Regenxbio in Q1 2021 and held it in 4 quarters.
  • Eaton Vance Management's Regenxbio position peaked at $20K in Q4 2021.
  • 188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.